AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?

Core Insights - Pfizer (PFE) and AstraZeneca (AZN) are leading pharmaceutical companies with significant oncology segments, contributing 27% and 44% to their total revenues respectively [1][2] - Both companies have strong R&D pipelines that could drive future growth, but they face different challenges and opportunities in the current market [3] Pfizer Overview - Pfizer's oncology revenues grew by 8% in 2025, supported by products like Xtandi and Lorbrena [4] - Non-COVID operational revenues increased by 6% in 2025, with recently launched and acquired products generating $10.2 billion, growing approximately 14% year-over-year [5] - Pfizer invested around $9 billion in M&A deals in 2025, focusing on enhancing its pipeline through acquisitions [6] - The company anticipates a decline in COVID product sales, projecting revenues of around $5 billion in 2026, down from $6.7 billion in 2025 [7] - Pfizer expects a significant revenue impact from the loss of exclusivity for key products between 2026-2030, estimating a $1.5 billion sales drop in 2026 [8] AstraZeneca Overview - AstraZeneca has 16 blockbuster drugs, contributing to an 8% revenue growth and 11% core EPS growth in 2025 [9][10] - The company targets mid-to-high single-digit revenue growth for 2026 and aims for $80 billion in total revenues by 2030 [12] - AstraZeneca's newer drugs have offset losses from mature brands, and the rare disease segment is showing improvement [10] - The company plans to launch 20 new medicines by 2030, with many expected to generate over $5 billion in peak-year revenues [12] - AstraZeneca faces challenges such as generic competition and ongoing investigations in its China subsidiary [13] Financial Estimates Comparison - The Zacks Consensus Estimate for AstraZeneca's 2026 sales and EPS implies a year-over-year increase of 6.0% and 123.6% respectively [14] - In contrast, Pfizer's estimates indicate a decline of 2.5% in sales and 7.8% in EPS for 2026 [16] Stock Performance and Valuation - Over the past year, Pfizer's stock rose by 1.8%, while AstraZeneca's stock increased by 40.6% [18] - AstraZeneca's shares trade at a forward P/E ratio of 20.12, while Pfizer's shares are at 9.11, indicating a more attractive valuation for Pfizer [19] - Pfizer offers a dividend yield of 6.4%, significantly higher than AstraZeneca's yield of around 1% [22] Investment Outlook - AstraZeneca is viewed as a safer investment due to its clearer growth targets and efficient profitability, despite Pfizer's lower valuation and higher dividend yield [25]